Insider Selling: uniQure (NASDAQ:QURE) Director Sells $630,592.06 in Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Gut also recently made the following trade(s):

• On Thursday, November 6th, Robert Gut sold 31,434 shares of uniQure stock. The shares were sold at an average price of $27.26, for a total value of $856,890.84.

uniQure Trading Up 3.9%

NASDAQ:QURE opened at $22.84 on Friday. The stock has a market cap of $1.42 billion, a P/E ratio of -5.20 and a beta of 0.68. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The stock has a 50-day simple moving average of $24.77 and a 200-day simple moving average of $27.72.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. As a group, analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

QURE has been the topic of several research reports. Chardan Capital reissued a “buy” rating and set a $53.00 price objective on shares of uniQure in a research report on Thursday, December 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, October 8th. UBS Group set a $95.00 target price on shares of uniQure in a research note on Thursday, September 25th. Finally, William Blair reaffirmed a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.82.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC boosted its position in shares of uniQure by 22.6% during the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock worth $259,422,000 after purchasing an additional 819,444 shares in the last quarter. Aberdeen Group plc boosted its holdings in uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in uniQure during the second quarter worth about $29,217,000. Franklin Resources Inc. increased its holdings in uniQure by 23.9% in the third quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock valued at $116,073,000 after buying an additional 383,066 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after acquiring an additional 1,491,486 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.